Mucormycosis and its prosthodontic management: A review
Journal of Advances in Dental Practice and Research · 2022
DOI: 10.25259/jadpr_11_2022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Advances in Dental Practice and Research, 2022. Verfasst von Rohit Balaji Patil und 4 weiteren Autor:innen. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
Coronavirus disease 2019 (COVID-19), during the second wave in early 2021, has created disastrous chaos. Adding more burdens to such a challenging situation, mucormycosis is an angioinvasive, fulminant fungal infection has seen a sudden raise in patients with COVID-19. Mucormycosis commonly affects the patients with compromised immunity. Early diagnosis, elimination of the predisposing factor, and antifungal therapy along with surgical debridement are the key factors responsible for successful treatment and patient survival. Mucormycosis is presented by various clinical forms. This paper reviews about the clinical presentation, diagnosis, and various treatment modalities for managing mucormycosis patients.
Zitieren
APA
Patil, R. B., Chandak, A., Radke, U., Sahai, R., & Kumbhare, R. (2022). Mucormycosis and its prosthodontic management: A review. Journal of Advances in Dental Practice and Research. https://doi.org/10.25259/jadpr_11_2022
Vancouver
Patil RB, Chandak A, Radke U, Sahai R, Kumbhare R. Mucormycosis and its prosthodontic management: A review. Journal of Advances in Dental Practice and Research. 2022. doi:10.25259/jadpr_11_2022
BibTeX
@article{Patil2022,
author = {Patil, Rohit Balaji and Chandak, Anuj and Radke, Usha and Sahai, Richa and Kumbhare, Ruchita},
title = {Mucormycosis and its prosthodontic management: A review},
journal = {Journal of Advances in Dental Practice and Research},
year = {2022},
doi = {10.25259/jadpr_11_2022}
}
EUVIMED